Other BCL6 small molecule inhibitors, such as FX1, significantly reduced CML CD34+ cells’ colony-forming ability, in combination with TKI (Madapura et al., 2017). Here, BCL6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.